Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer

Japanese study (n=804) failed to show the superiority of pemetrexed plus cisplatin vs vinorelbine plus cisplatin at a median of 45.2 months (median recurrence-free survival 38.9 vs 37.3 months; HR 0.98; 95% CI 0.81 to 1.20) but demonstrated better tolerability.

Source:

Journal of Clinical Oncology